Voices
EA8192
ECOG-ACRIN Cancer Research Group/X

EA8192 Trial for High Grade Upper Tract Urothelial Cancer is Enrolling – ECOG-ACRIN Cancer Research Group

ECOG-ACRIN Cancer Research Group shared a post on X:

“Urothelial cancer is the most common type of bladder cancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high-grade upper tract urothelial cancer prior to nephroureterectomy.”

Read further.

More posts featuring ECOG-ACRIN Cancer Research Group.

bladder cancer cancer Durvalumab EA8192 ECOG-ACRIN Cancer Research Group OncoDaily Oncology urothelial cancer